Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
arise, arising, authoritative, calendar, capacity, clarify, Codification, compelled, conclusion, condensed, consummate, CPA, declined, dispute, distressed, drawn, economic, encouraging, ensuing, essentially, experienced, explanation, favorable, feedback, flat, footnote, foreseeable, GAAP, Griffin, hand, headcount, hierarchy, insufficiently, literature, minimal, misleading, modest, nongovernmental, nonrecurring, orbec®, orderly, outlined, permitted, premium, presumption, quantify, saving, Schnittker, sell, supersede, technique, terrorism, thereto, unchanged, variable, Volume
Removed:
administer, adsorbed, alternate, antigen, approximate, Autoimmune, AVA, azathioprine, bacterium, bioequivalence, bioequivalent, cavity, cellular, challenging, characterizing, collectible, College, Collier, combine, commit, commonly, Concurrently, consulting, cyclosporine, debt, determinant, dosage, doubtful, efficiently, effort, elderly, engineered, Epstein, experience, exploring, family, fatal, feasibility, financed, flow, generate, Harvard, holotoxin, immunosuppressant, improve, improved, impure, Imuran, inhaled, insurance, intend, Joel, John, limit, medicine, methotrexate, mixture, multiple, naturally, negotiation, niche, Notice, observation, ongoing, OraprineTM, originally, PA, pre, prescribed, President, preventing, processed, processing, profile, prospective, purified, pursue, rejection, relating, role, rPA, SBIR, School, senior, serial, solid, statutory, strong, strongly, suspended, suspension, Topical, transplant, transplanted, treating, twelve, ulcerative, unable, uncollectible, volatility
Filing tables
Filing exhibits
Related press release
SNGX similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Form 10-Q of DOR BioPharma, Inc. (the “Company”) for the fiscal quarter ended June 30, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| August 14, 2009 | /s/ Christopher J. Schaber | |
| Christopher J. Schaber, Ph.D. | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) |